Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease

Affiliations

Editorial

Stephanie A Vuijk et al. Aliment Pharmacol Ther. 2022 Dec.

. 2022 Dec;56(11-12):1619-1620.

doi: 10.1111/apt.17243.

¹ Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.

No abstract available

Comment on

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
Burgess CJ, Jackson R, Chalmers I, Russell RK, Hansen R, Scott G, Henderson P, Wilson DC. Burgess CJ, et al. Aliment Pharmacol Ther. 2022 Nov;56(10):1453-1459. doi: 10.1111/apt.17217. Epub 2022 Oct 4. Aliment Pharmacol Ther. 2022. PMID: 36196524 Free PMC article.

1. Burgess C, Jackson R, Chalmers I, et al. The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study. Aliment Pharmacol Ther. 2022; 59:1453-1459.
1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010;59(2):141-7.
1. van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical Management of Paediatric Crohn's disease: an ECCO-ESPGHAN Guideline update. J Crohns Colitis. 2020;15:171-94. https://doi.org/10.1093/ecco-jcc/jjaa161
1. Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162(4):1147-1159 e1144.
1. Severs M, Oldenburg B, van Bodegraven AA, Siersema PD, Mangen MJ, initiative of Crohn’s and Colitis. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11(3):289-96.